Market ExpansionThe launch of Zoryve cream into atopic dermatitis (AD) is underway, with the previously announced partnership with Kowa providing commercial capabilities addressing the primary care market.
Product ApprovalZoryve cream 0.15% received FDA approval for the treatment of mild-to-moderate atopic dermatitis in adults and children aged ≥6 yrs.
Sales PerformanceARQT reported total 2Q24 sales of $30.9MM (+43% Q/Q) above the Street's $29.1MM, driven by strength from both the cream ($17.3MM, +15% Q/Q) and foam ($13.6MM, +109% Q/Q) products.